Literature DB >> 18585853

Dendritic cells dysfunction in tumour environment.

Karim Bennaceur1, Jessica Chapman, Leila Brikci-Nigassa, Kamel Sanhadji, Jean-louis Touraine, Jacques Portoukalian.   

Abstract

Several studies indicate that most tumours are immunogenic and they rarely succeed to induce an efficient immune response. Many mechanisms have been involved in the tumour escape from host immune surveillance. The tumour microenvironment has emerged as an important component contributing to dendritic cells (DCs) dysfunction. There is evidence that DCs play a key role in the induction of tumour-specific immune responses, especially via cross-priming through MHC-class I antigens presentation. In this review we will discuss the potential role of the tumour microenvironment in DCs dysfunction.

Entities:  

Mesh:

Year:  2008        PMID: 18585853     DOI: 10.1016/j.canlet.2008.05.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.

Authors:  Hideki Fujita; Mayte Suárez-Fariñas; Hiroshi Mitsui; Juana Gonzalez; Mark J Bluth; Shali Zhang; Diane Felsen; James G Krueger; John A Carucci
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

Review 2.  Directing dendritic cell immunotherapy towards successful cancer treatment.

Authors:  Rachel Lubong Sabado; Nina Bhardwaj
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

3.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

Review 4.  Features of responding T cells in cancer and chronic infection.

Authors:  Peter S Kim; Rafi Ahmed
Journal:  Curr Opin Immunol       Date:  2010-03-06       Impact factor: 7.486

Review 5.  Dendritic cell-based immunotherapy.

Authors:  Rachel L Sabado; Sreekumar Balan; Nina Bhardwaj
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

Review 6.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

7.  Effect of siRNA-mediated downregulation of VEGF in Tca8113 cells on the activity of monocyte-derived dendritic cells.

Authors:  Yan-Hong Ni; Zhi-Yong Wang; Xiao-Feng Huang; Pei-Hua Shi; Wei Han; Ya-Yi Hou; Zi-Chun Hua; And Qin-Gang Hu
Journal:  Oncol Lett       Date:  2012-01-16       Impact factor: 2.967

8.  The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.

Authors:  Tyler R McCaw; Mei Li; Dmytro Starenki; Sara J Cooper; Mingyong Liu; Selene Meza-Perez; Rebecca C Arend; Donald J Buchsbaum; Andres Forero; Troy D Randall
Journal:  Cancer Immunol Immunother       Date:  2018-10-17       Impact factor: 6.968

9.  Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.

Authors:  Emily L Williams; Stuart N Dunn; Sonya James; Peter W Johnson; Mark S Cragg; Martin J Glennie; Juliet C Gray
Journal:  Clin Cancer Res       Date:  2013-05-06       Impact factor: 12.531

10.  Influence of immunotherapy with autologous dendritic cells on innate and adaptive immune response in cancer.

Authors:  Bruna F Matias; Tânia M de Oliveira; Cláudia M Rodrigues; Douglas R Abdalla; Letícia Montes; Eddie F C Murta; Márcia A Michelin
Journal:  Clin Med Insights Oncol       Date:  2013-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.